These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24278155)

  • 1. Rapid molecular testing for TB to guide respiratory isolation in the U.S.: a cost-benefit analysis.
    Millman AJ; Dowdy DW; Miller CR; Brownell R; Metcalfe JZ; Cattamanchi A; Davis JL
    PLoS One; 2013; 8(11):e79669. PubMed ID: 24278155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-benefit analysis of Xpert MTB/RIF for tuberculosis suspects in German hospitals.
    Diel R; Nienhaus A; Hillemann D; Richter E
    Eur Respir J; 2016 Feb; 47(2):575-87. PubMed ID: 26647440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of screening strategies for pulmonary tuberculosis among hospitalized patients in a low-burden setting: cost-effectiveness of GeneXpert MTB/RIF compared to smear microscopy.
    Hickey AJ; Cummings MJ; Zafari Z; Louh IK; Li J; O'Donnell MR
    Infect Control Hosp Epidemiol; 2022 Jul; 43(7):892-897. PubMed ID: 34154681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.
    Steingart KR; Sohn H; Schiller I; Kloda LA; Boehme CC; Pai M; Dendukuri N
    Cochrane Database Syst Rev; 2013 Jan; (1):CD009593. PubMed ID: 23440842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Rapid Molecular Testing With Duration of Respiratory Isolation for Patients With Possible Tuberculosis in a US Hospital.
    Chaisson LH; Duong D; Cattamanchi A; Roemer M; Handley MA; Schillinger D; Sur M; Pham P; Lin MA; Goldman LE; Quan J; Perez S; Healy M; Higashi J; Winston L; Haller B; Luetkemeyer AF; Davis JL
    JAMA Intern Med; 2018 Oct; 178(10):1380-1388. PubMed ID: 30178007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microscopic observation drug-susceptibility assay vs. Xpert
    Wikman-Jorgensen PE; Llenas-García J; Pérez-Porcuna TM; Hobbins M; Ehmer J; Mussa MA; Ascaso C
    Trop Med Int Health; 2017 Jun; 22(6):734-743. PubMed ID: 28380276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the patient and health system impacts of alternative xpert® MTB/RIF algorithms for the diagnosis of pulmonary tuberculosis in Addis Ababa, Ethiopia.
    Tesfaye A; Fiseha D; Assefa D; Klinkenberg E; Balanco S; Langley I
    BMC Infect Dis; 2017 May; 17(1):318. PubMed ID: 28464797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Point-of-care Xpert® MTB/RIF for smear-negative tuberculosis suspects at a primary care clinic in South Africa.
    Van Rie A; Page-Shipp L; Hanrahan CF; Schnippel K; Dansey H; Bassett J; Clouse K; Scott L; Stevens W; Sanne I
    Int J Tuberc Lung Dis; 2013 Mar; 17(3):368-72. PubMed ID: 23407225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis.
    Vassall A; van Kampen S; Sohn H; Michael JS; John KR; den Boon S; Davis JL; Whitelaw A; Nicol MP; Gler MT; Khaliqov A; Zamudio C; Perkins MD; Boehme CC; Cobelens F
    PLoS Med; 2011 Nov; 8(11):e1001120. PubMed ID: 22087078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.
    Scott LE; McCarthy K; Gous N; Nduna M; Van Rie A; Sanne I; Venter WF; Duse A; Stevens W
    PLoS Med; 2011 Jul; 8(7):e1001061. PubMed ID: 21814495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting.
    Theron G; Peter J; van Zyl-Smit R; Mishra H; Streicher E; Murray S; Dawson R; Whitelaw A; Hoelscher M; Sharma S; Pai M; Warren R; Dheda K
    Am J Respir Crit Care Med; 2011 Jul; 184(1):132-40. PubMed ID: 21493734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Xpert MTB/RIF Ultra performance for pulmonary tuberculosis diagnosis on smear-negative respiratory samples in a French centre.
    Hodille E; Maisson A; Charlet L; Bauduin C; Genestet C; Fredenucci I; Rasigade JP; Lina G; Dumitrescu O
    Eur J Clin Microbiol Infect Dis; 2019 Mar; 38(3):601-605. PubMed ID: 30680567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States.
    Choi HW; Miele K; Dowdy D; Shah M
    Int J Tuberc Lung Dis; 2013 Oct; 17(10):1328-35. PubMed ID: 24025386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of GeneXpert MTB/RIF assay on triage of respiratory isolation rooms for inpatients with presumed tuberculosis: a hypothetical trial.
    Chaisson LH; Roemer M; Cantu D; Haller B; Millman AJ; Cattamanchi A; Davis JL
    Clin Infect Dis; 2014 Nov; 59(10):1353-60. PubMed ID: 25091300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensified tuberculosis case-finding in HIV-positive adults managed at Ethiopian health centers: diagnostic yield of Xpert MTB/RIF compared with smear microscopy and liquid culture.
    Balcha TT; Sturegård E; Winqvist N; Skogmar S; Reepalu A; Jemal ZH; Tibesso G; Schön T; Björkman P
    PLoS One; 2014; 9(1):e85478. PubMed ID: 24465572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of different Xpert MTB/Rif implementation strategies in programmatic settings at the regional referral hospitals in Uganda: Evidence for country wide roll out.
    Muttamba W; Ssengooba W; Sekibira R; Kirenga B; Katamba A; Joloba M
    PLoS One; 2018; 13(3):e0194741. PubMed ID: 29566056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicomponent strategy with decentralised molecular testing for tuberculosis in Uganda: a cost and cost-effectiveness analysis.
    Thompson RR; Nalugwa T; Oyuku D; Tucker A; Nantale M; Nakaweesa A; Musinguzi J; Reza TF; Zimmer AJ; Ferguson O; Turyahabwe S; Joloba M; Cattamanchi A; Katamba A; Dowdy DW; Sohn H
    Lancet Glob Health; 2023 Feb; 11(2):e278-e286. PubMed ID: 36669808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of the Xpert(®) MTB/RIF assay for diagnosing pulmonary tuberculosis comorbidity and multidrug-resistant TB in obstetrics and gynaecology inpatient wards at the University Teaching Hospital, Lusaka, Zambia.
    Bates M; Ahmed Y; Chilukutu L; Tembo J; Cheelo B; Sinyangwe S; Kapata N; Maeurer M; O'Grady J; Mwaba P; Zumla A
    Trop Med Int Health; 2013 Sep; 18(9):1134-1140. PubMed ID: 23834035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India's public sector.
    Lee DJ; Kumarasamy N; Resch SC; Sivaramakrishnan GN; Mayer KH; Tripathy S; Paltiel AD; Freedberg KA; Reddy KP
    PLoS One; 2019; 14(7):e0218890. PubMed ID: 31265470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Added value of molecular assay Xpert MTB/RIF compared to sputum smear microscopy to assess the risk of tuberculosis transmission in a low-prevalence country.
    Opota O; Senn L; Prod'hom G; Mazza-Stalder J; Tissot F; Greub G; Jaton K
    Clin Microbiol Infect; 2016 Jul; 22(7):613-9. PubMed ID: 27139592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.